Inhibikase Therapeutics, Inc. (IKT) vs Q32 Bio Inc. (QTTB)
Inhibikase Therapeutics, Inc. and Q32 Bio Inc. are both Biotechnology companies. Inhibikase Therapeutics, Inc. and Q32 Bio Inc. are of similar size ($293.0M and $282.8M). Inhibikase Therapeutics, Inc. has negative trailing earnings, so its P/E is not meaningful; Q32 Bio Inc. trades at 2.9×. Inhibikase Therapeutics, Inc. grew revenue faster over the last twelve months: 110.9% against −307.3%. Across the 11 metrics below, Q32 Bio Inc. leads on 10 and Inhibikase Therapeutics, Inc. on 1.
Valuation
Profitability
| Metric | IKT | QTTB | Biotechnology median |
|---|---|---|---|
| Gross margin | 100.00% | 100.00% | 65.16% |
| Operating margin | 0.00% | 0.00% | 0.00% |
| Net margin | 0.00% | 0.00% | 0.00% |
| Free cash flow margin | 0.00% | 0.00% | 0.00% |
| Return on equity | (51.96%) | 72.14% | (57.72%) |
| Return on assets | (48.04%) | 37.13% | (49.22%) |
| Return on invested capital | 0.00% | 0.00% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack